MBIO - Mustang Bio: Slow Steady Progress Towards Multiple Gene And CAR-T Therapy Goals
Investment Thesis
Mustang Bio share price performance since joining Nasdaq. Source: TradingView
Mustang Bio (MBIO) is looking like an increasingly attractive investment opportunity within the gene and CAR-T therapy space.
Mustang is a wholly owned subsidiary of Fortress Bio, and operates the same strategy as its parent company, identifying promising therapeutic candidates at research centers and medical establishments and in-licensing them or acquiring an ownership interest, in exchange for funding research and development, and milestone and royalty payments in the event the candidates are eventually out-licensed or brought to market.
Mustang has